Osel’s LACTIN-V is a live biotherapeutic product addressing women’s health disorders. It incorporates a single species and strain of Lactobacillus that is part of the natural microbiome of healthy women and that has been selected for features that restore health and prevent recurrence of infection. In particular, LACTIN-V fosters the conditions observed in healthy women that combat the pathogenic bacteria and dysbiosis observed in bacterial vaginosis and urinary tract infections. LACTIN-V is delivered vaginally with a proprietary applicator.

Several clinical trials with LACTIN-V have already been completed. [LINK TO relevant CLINICAL PUBLICATIONS]. These studies have demonstrated the safety of the product, and show that LACTIN-V use is associated with favorable outcomes for patients with bacterial vaginosis and recurrent urinary tract infections. In a seminal study, women who took LACTIN-V and achieved a high level of LACTIN-V colonization had a significant decrease in rUTI (50%) versus those that did not (P<0.01)

LACTIN-V is being further evaluated in a pivotal clinical trial today. [LINK to CLINICAL TRIALS of LACTIN-V].